Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

Amgen

Status and phase: Completed; Phase 3

Conditions: Pediatric Plaque Psoriasis

Treatments: Drug: Etanercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT00141921

20050111

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

Full description

This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).

Enrollment: 182 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrollment on previous Amgen study 20030211 (NCT00078819)

Exclusion criteria

• Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

182 participants in 1 patient group

Etanercept

Experimental group

Description:

Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.

Treatment:

Drug: Etanercept